Status: Recruiting
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.
Participants needed: 32
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Jul 24, 2026Locations: 1
Eligibility criteria
Having provided written informed consent, and be able to follow clinical trial p... [+29]
Clinical symptomatic brain metastasis is defined as untreated and symptomatic, o... [+19]